East Bay cancer drug developer targets $100 million IPO

Arcus Biosciences Inc., launched by scientists after the $1.25 billion buyout of their previous company, hopes to raise $100 million in an initial public offering to pursue an aggressive clinical trial schedule for drugs that help the immune system find and attack cancer. The 83-employee Hayward company's IPO filing Friday with the Securities and Exchange Commission said the cash will fund clinical development of its main drugs, called AB-928 and AB-122, and support other drug candidates and hireā€¦
Source: bizjournals.com Health Care:Biotechnology headlines - Category: Biotechnology Authors: Source Type: news